原发性肝癌双灌注介入治疗前后血清TNF-α和sFas水平的改变及意义探讨

The change in serum TNF-α and sFas among primary liver cancer patients before and after Double intra-arterial infusion of anti-cancer agent

目的了解原发性肝癌双灌注介入前后血清TNF-α、血清可溶性Fas(sFas)水平的变化,并探讨其临床意义。方法本研究选取75例原发性肝癌患者,其中30例行TACE治疗,45例行TACE联合脾动脉化疗药物灌注治疗,每个病例分别在术前一天、术后二周测定血清TNF-α、sFas,同时对所有病例进行近期疗效判定,另设30例正常对照组。结果肝癌患者的血清TNF-α和sFas的水平均明显高于正常对照组(P<0.01),TACE和双灌注治疗后血清TNF-α和sFas的水平均明显低于治疗前(P<0.01),双灌注治疗组治疗后血清TNF-α和sFas的水平分别低于TACE组治疗后水平(P<0.05),在双灌注组中,近期疗效达有效者血清TNF-α和sFas的水平明显低于无效者(P<0.01)。结论原发性肝癌的双灌注介入治疗后血清TNF-α和sFas的水平明显降低,检测血清TNF-α和sFas的水平可以有助于预后估计。

Objective To study the clinical significance of change in serum TNF-αand sFas among primary liver cancer patients before and after Double intra-arterial infusion of anti-cancer agent.Methods A total of 75 patients with primary liver cancer were treated with TACE（35 patients）,and TACE Combined with Splenic Arterial Set-catheter Infusion（45 patients）.In addition,30 patients were included in the study as a normal control group.The patients serum TNFαand sFas were determined before and two weeks after therapy and all the patients were evaluated for the effect of treatment simultaneously.Results Serum TNF-α and sFas levels of primary liver cancer patients were higher than the normal control group（P 〈0.01）.Serum TNF-α and sFas levels in patients treated with TACE and Double intra-arterial infusion of anti-cancer agents were lower than the control group（P 〈0.01）.The serum TNF-α and sFas levels of patients treated with Double intra-arterial infusion anti-cancer agent were lower than the TACE treatment group（P〈 0.05）.Double intra-arterial infusion anti-cancer agent therapy had shown a significant effect on serum TNF-α and sFas＇s levels of the treated patients than the patients that were not treated（P〈 0.01）.Conclusion Patients that were treated with Double intraarterial infusion of anti-cancer agent were shown a significant decrease in serum TNF-α and sFas measurement.Therefore,these parameters can be used to estimate disease prognosis.